A fixed-dose combination therapy for the management of postmenopausal osteoporosis and other bone disorders. It provides a comprehensive approach by combining a bisphosphonate (Ibandronic Acid) for bone resorption inhibition with essential bone-building minerals (Calcium, Zinc) and the active form of Vitamin D (Calcitriol) to enhance calcium absorption and bone mineralization. This combination addresses multiple facets of bone metabolism and is a cornerstone of osteoporosis management in the Indian context, where dietary deficiencies are common.
Adult: Ibandronic Acid 150mg: ONE tablet orally, once every month. Calcium (500mg) + Calcitriol (0.25mcg) + Zinc (20mg): ONE tablet orally, DAILY. The monthly Ibandronate and daily supplements are NOT taken simultaneously.
Note: CRITICAL: Ibandronic Acid 150mg Tablet: Take on the same date each month, first thing in the morning, at least 60 minutes before the first food, drink (other than plain water), or any other medication (including the Calcium/Calcitriol/Zinc tablet). Swallow whole with a full glass (180-240ml) of plain water. Remain upright (sitting or standing) for at least 60 minutes after ingestion. Do not chew or suck. Calcium/Calcitriol/Zinc Tablet: Take once daily, preferably with a meal to improve tolerance and absorption. MUST be taken at a different time of day than the Ibandronate tablet (minimum 60-minute gap, preferably afternoon/evening).
The combination exerts a multi-targeted effect on bone remodeling. Ibandronic Acid potently inhibits osteoclast-mediated bone resorption by disrupting the mevalonate pathway, leading to osteoclast apoptosis. Calcitriol (1,25-dihydroxyvitamin D3) enhances intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and directly stimulates osteoblasts for bone formation. Calcium provides the essential mineral substrate for bone mineralization. Zinc acts as a cofactor for over 300 enzymes, including alkaline phosphatase and collagenase, crucial for bone matrix synthesis and mineralization.
Pregnancy: Category C (Ibandronate - animal teratogen), Category C (Calcitriol - high doses teratogenic in animals). Contraindicated. Bisphosphonates can be incorporated into fetal skeleton. Risk of fetal hypocalcemia. Use only if potential benefit justifies extreme risk.
Driving: Generally no effect. However, dizziness or vertigo (rare side effects) may impair ability.
| Calcium Supplements/Antacids (high dose), Iron, Magnesium, Aluminum | Severely reduce absorption of Ibandronic Acid if taken concurrently. | Major |
| Other Bisphosphonates (Alendronate, Risedronate) or Denosumab | Increased risk of hypocalcemia and skeletal adverse events. Not recommended. | Major |
| Loop Diuretics (Furosemide) | May increase risk of hypercalcemia with Calcitriol. | Moderate |
| Thiazide Diuretics | Increase renal calcium reabsorption, potentiating risk of hypercalcemia. | Moderate |
| Digoxin | Hypercalcemia potentiates digitalis toxicity (arrhythmias). | Major |
| CYP3A4 Inducers (Rifampicin, Phenytoin, Carbamazepine) | May increase metabolism of Calcitriol, reducing its efficacy. | Moderate |
| Corticosteroids | Antagonize the effect of Calcitriol on calcium absorption; also increase osteoporosis risk. | Moderate |
| Quinolone/Tetracycline Antibiotics | Calcium and Zinc can chelate these, reducing their absorption. Separate by 2-4 hours. | Moderate |
Same composition (Calcium (500mg) + Calcitriol (0.25mcg) + Zinc (20mg) + Ibandronic Acid (150mg)), different brands: